Protocol Ledger

NCT07005128 · Phase III · ACTIVE NOT RECRUITING

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Interventional Phase III clinical trial protocol NCT07005128 sponsored by Amgen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-18 Enrollment: 350 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07005128
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)350 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07005128
Protocol FieldVerified Registry Value
NCT IdentifierNCT07005128
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment350 participants (ACTUAL)
Registered Start Date2025-08-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07005128
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI